

AMENDMENTS

Listing of Claims:

The following listing of claims replaces all previous listings or versions thereof:

1.-38 (cancelled)

39. (previously presented) A method of identifying a modulator of a Fortilin polypeptide comprising:

- (a) contacting an isolated Fortilin polypeptide comprising the amino acid sequence of SEQ ID NO:2 with a candidate substance; and
- (b) assaying whether the candidate substance enhances or inhibits the Fortilin polypeptide activity, wherein a candidate substance that enhances or inhibits Fortilin polypeptide activity is a modulator of the Fortilin polypeptide.

40. (previously presented) The method of claim 39, wherein the assaying compares the activity of the Fortilin polypeptide in the presence and absence of the candidate substance.

41. – 45. (cancelled)

46. (previously presented) The method of claim 39, wherein the assaying is done by determining whether a p53-Fortilin interaction is disrupted.

47. (previously presented) The method of claim 39, wherein the assaying is done by determining whether a MCL1-Fortilin interaction is disrupted.

48.-62. (cancelled)

63. (previously presented) The method of claim 39, wherein the candidate substance is a polypeptide.

64. (previously presented) The method of claim 63, wherein the polypeptide is an antibody.

65. (previously presented) The method of claim 39, wherein the candidate substance is a nucleic acid.
66. (previously presented) The method of claim 39, wherein the candidate substance is a small molecule.
67. (cancelled)
68. (previously presented) A method of identifying a modulator of a Fortilin polypeptide comprising:
- (a) contacting a candidate modulator with isolated, recombinant cells expressing a Fortilin polypeptide comprising the amino acid sequence of SEQ ID NO:2;
 - (b) measuring the level of Fortilin activity or expression of the cell; and,
 - (c) comparing the level of Fortilin activity or expression of the cells to the level of Fortilin activity or expression of cells not contacted with the candidate modulator, wherein a difference between the level of Fortilin activity or expression indicates that the candidate modulator is a modulator of a Fortilin polypeptide.
69. (previously presented) The method of claim 68, wherein the level of Fortilin activity is measured.
70. (previously presented) The method of claim 69, wherein the Fortilin activity is protein binding.
71. (previously presented) The method of claim 70, wherein the Fortilin activity is p53 binding.
72. (previously presented) The method of claim 69, wherein the Fortilin activity is MCL1 binding.

73. (previously presented) The method of claim 69, wherein the Fortilin activity is cell cycle progression.
74. (previously presented) The method of claim 69, wherein the Fortilin activity is prevention of apoptosis.
75. (previously presented) The method of claim 68, wherein the level of Fortilin expression is measured.
76. (previously presented) The method of claim 75, wherein the level of Fortilin polypeptide is measured.
77. (previously presented) The method of claim 75, wherein the level of Fortilin mRNA is measured.
78. (previously presented) The method of claim 75, wherein Fortilin half-life is measured.
79. (previously presented) The method of claim 68, wherein the candidate substance is a polypeptide.
80. (previously presented) The method of claim 79, wherein the polypeptide is an antibody.
81. (previously presented) The method of claim 68, wherein the candidate substance is a nucleic acid.
82. (previously presented) The method of claim 81, wherein the nucleic acid comprises at least 20 contiguous nucleotides identical or complementary to SEQ ID NO:1.
83. (previously presented) The method of claim 68, wherein the candidate substance is a small molecule.

84.-87. (cancelled)

88. (previously presented) The method of claim 68, wherein the candidate modulator acts directly on a Fortilin gene or Fortilin RNA.

89.-92. (cancelled)